Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) - PubMed

Review

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)

Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Hum Reprod. 2004 Jan.

Abstract

Since the 1990 NIH-sponsored conference on polycystic ovary syndrome (PCOS), it has become appreciated that the syndrome encompasses a broader spectrum of signs and symptoms of ovarian dysfunction than those defined by the original diagnostic criteria. The 2003 Rotterdam consensus workshop concluded that PCOS is a syndrome of ovarian dysfunction along with the cardinal features hyperandrogenism and polycystic ovary (PCO) morphology. PCOS remains a syndrome and, as such, no single diagnostic criterion (such as hyperandrogenism or PCO) is sufficient for clinical diagnosis. Its clinical manifestations may include: menstrual irregularities, signs of androgen excess, and obesity. Insulin resistance and elevated serum LH levels are also common features in PCOS. PCOS is associated with an increased risk of type 2 diabetes and cardiovascular events.

Similar articles

• Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.

  Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Fertil Steril. 2004 Jan;81(1):19-25. doi: 10.1016/j.fertnstert.2003.10.004. Fertil Steril. 2004. PMID: 14711538

• Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism.

  Dewailly D, Pigny P, Soudan B, Catteau-Jonard S, Decanter C, Poncelet E, Duhamel A. Dewailly D, et al. J Clin Endocrinol Metab. 2010 Sep;95(9):4399-405. doi: 10.1210/jc.2010-0334. Epub 2010 Jul 7. J Clin Endocrinol Metab. 2010. PMID: 20610596

• Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature.

  Azziz R. Azziz R. J Clin Endocrinol Metab. 2006 Mar;91(3):781-5. doi: 10.1210/jc.2005-2153. Epub 2006 Jan 17. J Clin Endocrinol Metab. 2006. PMID: 16418211

• Best methods for identification and treatment of PCOS.

  Artini PG, Di Berardino OM, Simi G, Papini F, Ruggiero M, Monteleone P, Cela V. Artini PG, et al. Minerva Ginecol. 2010 Feb;62(1):33-48. Minerva Ginecol. 2010. PMID: 20186113 Review.

• Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances.

  Spritzer PM. Spritzer PM. Arq Bras Endocrinol Metabol. 2014 Mar;58(2):182-7. doi: 10.1590/0004-2730000003051. Arq Bras Endocrinol Metabol. 2014. PMID: 24830595 Review.

Cited by

• Polycystic Ovarian Syndrome (PCOS): Does the Challenge End at Conception?

  Mirza FG, Tahlak MA, Rjeili RB, Hazari K, Ennab F, Hodgman C, Khamis AH, Atiomo W. Mirza FG, et al. Int J Environ Res Public Health. 2022 Nov 12;19(22):14914. doi: 10.3390/ijerph192214914. Int J Environ Res Public Health. 2022. PMID: 36429632 Free PMC article. Review.

• Multiomics Analysis Reveals Molecular Abnormalities in Granulosa Cells of Women With Polycystic Ovary Syndrome.

  Zhao R, Jiang Y, Zhao S, Zhao H. Zhao R, et al. Front Genet. 2021 May 18;12:648701. doi: 10.3389/fgene.2021.648701. eCollection 2021. Front Genet. 2021. PMID: 34084179 Free PMC article.

• Identification of epigenetic interactions between microRNA and DNA methylation associated with polycystic ovarian syndrome.

  Mao Z, Li T, Zhao H, Qin Y, Wang X, Kang Y. Mao Z, et al. J Hum Genet. 2021 Feb;66(2):123-137. doi: 10.1038/s10038-020-0819-6. Epub 2020 Aug 5. J Hum Genet. 2021. PMID: 32759991 Free PMC article.

• Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility.

  Panidis D, Tziomalos K, Papadakis E, Vosnakis C, Chatzis P, Katsikis I. Panidis D, et al. Endocrine. 2013 Dec;44(3):583-90. doi: 10.1007/s12020-013-9971-5. Epub 2013 Apr 27. Endocrine. 2013. PMID: 23625194 Review.

• A molecular mechanism underlying ovarian dysfunction of polycystic ovary syndrome: hyperandrogenism induces epigenetic alterations in the granulosa cells.

  Qu F, Wang FF, Yin R, Ding GL, El-Prince M, Gao Q, Shi BW, Pan HH, Huang YT, Jin M, Leung PC, Sheng JZ, Huang HF. Qu F, et al. J Mol Med (Berl). 2012 Aug;90(8):911-23. doi: 10.1007/s00109-012-0881-4. Epub 2012 Feb 21. J Mol Med (Berl). 2012. PMID: 22349439

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information